



UniversitätsKlinikum Heidelberg


Allogene Stammzelltransplantation: Jahresbericht 2007

**Sektion Stammzelltransplantation
Abteilung Innere Medizin V
Universitätsklinikum Heidelberg**

11.2.2008




Anzahl allogene Transplantationen






Spender


2005



2006




2007






Patienten


2005



2006




2007






Diagnosen


2004



2006



2007






Diagnosen im Einzelnen

AML CR1	12	Aggressive B	9
AML >CR1	16	CLL	6
MDS	8	FL/WM	2
		Hodgkin	6
ALL CR1	4		
ALL >CR1	6	Myelom	7
OMF	3	SAA	3
CML (BC)	3 (2)		
		Gesamt	87




Gesamtüberleben (alle)





Therapie-assoziierte Mortalität (alle)






Diagnosen im Einzelnen

AML CR1	12	Aggressive B	9
AML >CR1	16	CLL	6
MDS	8	FL/WM	2
		Hodgkin	6
ALL CR1	4		
ALL >CR1	6	Myelom	7
OMF	3	SAA	3
CML (BC)	3 (2)		
		Gesamt	87

Konditionierung in Aplasia


(Leukämie-freies Überleben, Heidelberg 2005-2007, Patienten mit AML/MDS primär oder refraktär)





Allo-SZT: Alter und Ergebnis

(Gesamtüberleben, Heidelberg 2005-2007, nur Patienten mit AML/MDS)






Diagnosen im Einzelnen

AML CR1	12	Aggressive B	9
AML >CR1	16	CLL	6
MDS	8	FL/WM	2
		Hodgkin	6
ALL CR1	4		
ALL >CR1	6	Myelom	7
OMF	3	SAA	3
CML (BC)	3 (2)		
		Gesamt	87




B-Zell-Lymphome: EFS 2005-2007





B-Zell-Lymphome: OS 2005-2007





...und sonst?



April 26–28, 2007 ■ Heidelberg, Germany

14th International Symposium on Recent Advances in Stem Cell Transplantation



Allo-SCT: Forschung

Adaptive Immunologie:	T Luft, M Conzelmann
CD40L und JAK2:	M Conzelmann, T Luft
GVHD-Monitoring:	T Luft, P Dreger
Engraftment-Syndrom:	M Rieger, T Luft
Allo-Studie Amyloidose:	S Schönland, U Hegenbart
Allo-Studien Myelom:	S Schönland, U Hegenbart
Allo-Studie CLL:	P Dreger, M Hensel, M Rieger
FL: allo-Indikationen	P Dreger, S Dietrich
MCL auto	M Rieger, M Witzens, P Dreger
AML: Aplasie-TPL	J Dengler, P Dreger
Maribavir	J Dengler, U Hegenbart, P Dreger



Allo-SCT: Publikationen 2007

Dreger P, Corradini P, Kimby E, et al (2007) Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. **Leukemia**, 21., 12-17.

Dreger P, Rieger M, Seyfarth B, Hensel M, Kneba M, Ho AD, Schmitz N, & Pott C (2007) Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: Effects on molecular response and clinical outcome. **Haematologica**, 92, 42-49.

Dreger P & Schmitz N, (2007) Autologous stem cell transplantation as part of first-line treatment of Waldenström's macroglobulinemia. **BBMT**, 13, 622-624.

Dreger P, Brand R & Michallet M (2007) Autologous stem cell transplantation for chronic lymphocytic leukemia. **Sem Hematol**, 44,246-251.

Gahrton G, Hegenbart U,... Schönland SO et al (2007) Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. **Haematologica** 92,:1513-18.

Hensel M, Dreger P & Ho AD (2007) IgM-Gammopathie: Differentialdiagnose, Klinik und Therapie. **Dt Ärzteblatt**; .

Luft T, Conzelmann M, ... Dreger P. (2007) Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. **Blood** 110:4235-42.

Platten M, Opitz C, Kohlhof P, Hegenbart U, Ho AD, Wick W (2007) Painful neuropathy due to intraneural leukemic spread in a patient with acute myeloid leukemia. **Neurology** 69:707

Rieger M, Witzens M, Hensel M,... Dreger P. (2007) Optimizing upfront autologous stem cell transplantation in mantle cell lymphoma: A comparison of different rituximab-based strategies. **DGHO** 2007

Rodionova E, Conzelmann M, ..., Luft T. (2006) GSK-3 mediates differentiation and activation of pro-inflammatory dendritic cells. **Blood** 109:1584-92

Schmitz N, Dreger P, Glass B & Sureda A (2007) Allogeneic transplantation in lymphoma: Current status **Haematologica**, 92, 1533-48

Ueno NT,Hegenbart U et al (2007) Allogeneic hematopoietic cell transplantation for metastatic breast cancer. **BMT** Dec 17.




Allo-SCT: Forschung

Adaptive Immunologie:	T Luft, M Conzelmann
CD40L und JAK2:	M Conzelmann, T Luft
GVHD-Monitoring:	T Luft, P Dreger
Engraftment-Syndrom:	M Rieger, T Luft
Allo-Studie Amyloidose:	S Schönland, U Hegenbart
Allo-Studien Myelom:	S Schönland, U Hegenbart
Allo-Studie CLL:	P Dreger, M Hensel, M Rieger
FL: allo-Indikationen	P Dreger, S Dietrich
MCL auto	M Rieger, M Witzens, P Dreger
AML: Aplasie-TPL	J Dengler, P Dreger
Maribavir	J Dengler, U Hegenbart, P Dreger

CLL: **U**nrelated and **R**elated **A**llogeneic
Transplantation **I**n **V**ery-high/high-risk disease
for leukemia **E**radication

= CURATIVE

GCLLG CURATIVE trial



High: REL <2y after PA comb;,
 Very high: PA ref; 17p-

GCLLG CURATIVE trial Status

- High-risk stratum: 115
Very-high-risk stratum: 89
to be randomized within 3 years
- **Funding granted by DFG (1,1 Mio)**
- Start: May 2008 in 26 centers from
Germany, Austria, Switzerland and
Canada



Allo-SCT sind

„von Dusch“

ML Knee

R Gruß

R Adam

...und das Team!

Station

F Bellos

S Deppisch

S Gaul

C Harter

L Scheuer

L Storm

M Villalobos

P Wuchter

A Martin

JW Schmier

Koordination

P Stadtherr

I Opitz

S Fichtner

Ambulanz

J Dengler

M Conzelmann

T Luft

S Schönland

K Maciol

A Pirch

D Prochaska

Case Manager

A Bondong

K Zerfaß

Psychologie

D Tönnessen

Labor

T Luft

M Conzelmann

M Moos

M Rieger

Sozialdienst

A Bergner

G Daiß

Finanzen & MDK

A Bondong

M Thalheimer

Anleitung

U Hegenbart

P Dreger

Aufsicht...

G Egerer

AD Ho

...alle Mitarbeiter der MedV